Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
ID: 352945Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352945

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-121.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" under the T32 Clinical Trial Not Allowed mechanism. This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, inviting applications from eligible higher education institutions to create training programs for predoctoral and postdoctoral researchers in various fields, including data science and behavioral research. The program is significant in addressing the growing challenges associated with AD/ADRD and aligns with the National Alzheimer's Project Act's goals of promoting team science and data-sharing collaborations. Interested institutions can apply starting April 25, 2024, with a maximum project period of five years and an anticipated funding amount of $2.7 million annually for 3-5 awards. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-121-Full-Announcement.html
    PAR-24-121.html
    The National Institutes of Health (NIH) is issuing a funding opportunity aimed at advancing institutional training programs for Alzheimer's Disease (AD) and AD-related dementias (ADRD) through the T32 Clinical Trial Not Allowed mechanism. This initiative is designed to build a diverse research workforce capable of leading interdisciplinary efforts in translational research related to AD/ADRD. The program invites applications from higher education institutions to create training that equips predoctoral and postdoctoral researchers with essential skills for conducting rigorous research across various domains, including behavioral science and data analysis. Key dates include an application opening on April 25, 2024, with a maximum project period of five years and an anticipated funding of $2.7 million annually for 3-5 awards. The proposal must emphasize the recruitment of diverse trainees and institutions, include plans for mentorship, and address the NIH's commitment to rigorous research practices. Applications are expected to follow strict guidelines, demonstrating program distinctiveness, a commitment to inclusion, and clear training objectives. This effort aligns with the goals of the National Alzheimer's Project Act which emphasizes team science and data-sharing collaborations to combat the challenges of AD/ADRD effectively.
    Similar Opportunities
    Institutional Translational Research Training Program (T32 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Institutional Translational Research Training Program (T32), a federal grant aimed at equipping advanced predoctoral students, postdoctoral fellows, and fellowship-stage clinicians with the skills necessary to advance basic research toward clinical application, particularly in the field of neuroscience. This program emphasizes a cohesive educational approach that integrates training in experimental design, statistical analysis, and effective communication, while fostering interdisciplinary collaboration among scientists and clinicians and providing exposure to industry and regulatory processes. The grant will cover stipends, tuition, and training-related expenses for a duration of two years, with a focus on enhancing diversity in biomedical research. Interested applicants can find more information and apply by May 25, 2026, and should direct inquiries to grantsinfo@nih.gov.
    NINDS Advanced Institutional Research Training Program (T32 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NINDS Advanced Institutional Research Training Program (T32), aimed at enhancing the training of well-qualified neuroscientists at the dissertation stage, postdoctoral fellows, and fellowship-stage clinicians. This program supports 1-2 years of mentorship and research development, focusing on diverse and rigorous training in neuroscience, including skills in scientific reasoning, experimental design, and statistical analysis, while prohibiting trainees from leading independent clinical trials. The initiative seeks to foster an inclusive research environment and bolster diverse representation within the research community, with awards covering stipends, tuition, travel, and essential training-related expenses. Applications are due by May 25 annually, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the official announcement link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-126.html.
    Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32), aimed at enhancing training for predoctoral students in neuroscience. This program supports a two-year curriculum that emphasizes experimental design, statistical methodology, and quantitative reasoning, preparing students for careers in neuroscience research through comprehensive training and research experience. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities and Hispanic-serving Institutions, with each institution allowed to submit one application based on NIH funding availability. Interested parties can find more information and application guidelines at the provided NIH link, with the application deadline set for May 25, 2025.
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIA Advanced Postdoctoral Career Transition Awards to promote diversity in translational research related to Alzheimer's disease and related dementias (AD/ADRD). This funding opportunity aims to support early-career investigators from underrepresented backgrounds, providing them with the necessary training and mentorship to develop critical research skills and transition into independent research roles. The program consists of two phases: the K99 phase for mentored training lasting up to two years, followed by the R00 phase, which offers independent research support for up to three years. Eligible applicants include various institutions and organizations, with a focus on enhancing the diversity of the research workforce. Interested parties should note that the application deadline is July 12, 2027, and can find more information at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Investigations into Alzheimer’s Disease-Related Dementias (ADRD) Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)." This grant aims to support research that investigates the interactions of multiple co-pathologies associated with ADRD, focusing on their cellular and molecular mechanisms and their impact on cognitive and functional impairments. The initiative is part of a broader commitment to advance neuroscience research and address public health challenges related to dementia, with particular emphasis on studies that explore co-pathologies such as tau and alpha-synuclein. Interested applicants can apply for funding up to $500,000, with applications due by October 4, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html.
    NINDS Alzheimers Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00 Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NINDS Alzheimer's Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00), aimed at supporting emerging independent researchers transitioning from mentored postdoctoral positions to tenure-track faculty roles in ADRD research. This grant program seeks to cultivate a diverse pool of skilled scientists by providing up to two years of mentored support followed by a three-year independent phase, contingent on securing a faculty position, while emphasizing research that does not involve leading independent clinical trials. The initiative aligns with the National Plan to Address Alzheimer’s Disease, focusing on enhancing research capabilities to combat cognitive decline and dementia. Interested applicants must adhere to eligibility criteria, including a maximum of four years of postdoctoral experience, and can find further details and application deadlines, which span from September 2024 to December 2026, at the provided NIH link. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.